Translational Therapeutics

Dr Adam Sharps' Group searches for novel therapeutic strategies to prevent the development of treatment resistance and to overcome the progression of cancer

Research, projects and publications in this group

The aim of the Translational Therapeutics Group is to better understand the biology of prostate, and other advanced cancers, to identify therapeutic strategies that can be rapidly translated to ‘proof of concept’ clinical studies to improve treatments for advanced cancer.

Dr Adam Sharp

Group Leader:

Translational Therapeutics Dr Adam Sharp

Dr Adam Sharp is Leader of the Translational Therapeutics Group and Honorary Consultant Medical Oncologist within the Prostate Cancer Targeted Therapies Group and Drug Development Unit at the ICR and The Royal Marsden NHS Foundation Trust.

Researchers in this group

.

Phone: +44 20 3437 6096

Email: [email protected]

Location: Sutton

I am a bioinformatician working in the Cancer Biomarkers and Translational Therapeutics Teams at the Institute of Cancer Research. I work with next generation sequencing data to understand prostate cancer biomarkers in advanced disease. I have a multidisciplinary background in medicinal chemistry and molecular biology, as well as bioinformatics expertise, particularly in transcriptomics, epigenomics, integrative omics and biostatistics.

Headshot of Souvik Das .

Phone: +44 20 3437 6831

Email: [email protected]

Location: Sutton

I am a Higher Scientific Officer in the Translational Therapeutics Team at the ICR. My focus is on leveraging apoptotic pathways to combat therapy resistance and study immunogenic responses. I also support the team in various projects, ranging from AR signalling to protein translation, with an aim to translate novel therapeutic strategies to combat lethal prostate cancer.

.

Phone: +44 20 3437 3517

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6230

Email: [email protected]

Location: Sutton

I am a Prostate Cancer UK Postdoctoral Travelling Fellow working in the Cancer Biomarkers and Translational Therapeutics teams at Institute of Cancer Research. I am currently focused on developing novel therapeutic strategies, as well as discovering vulnerabilities of advanced prostate cancer, to prevent the development of resistance against drugs currently used in clinical practise to tackle this disease.

.

Phone: +44 20 3437 6522

Email: [email protected]

Location: Sutton

Headshot of Joe Taylor .

Phone: +44 20 3437 6844

Email: [email protected]

Location: Sutton

I am a Postdoctoral Training Fellow working in the Translational Therapeutics team at the Institute of Cancer Research. My research is focused on the role of mRNA translation in prostate cancer, with a focus on discovering novel therapeutic vulnerabilities of advanced stage disease and to identify resistance mechanisms for drugs that are used in the clinic.

.

Phone: +44 20 3437 6364

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6519

Email: [email protected]

Location: Sutton

I am a CRUK Clinical Research Training Fellow working in the Translational Therapeutics Team and the Prostate Cancer Targeted Therapies Group at the Institute of Cancer Research and Royal Marsden Hospital. I have an interest in developing novel therapeutic approaches to improve outcomes for men with advanced prostate cancer. My PhD is focused on the pre-clinical development and translation of strategies to target the intrinsic apoptosis pathway.

Headshot of Wanting Zeng .

Phone: +44 20 3437 6802

Email: [email protected]

Location: Sutton

I am a PhD student in the Translational Therapeutics Team at the ICR. My research project focuses on regulating RNA processing in lethal prostate cancer. I hope to discover new strategies, in order to revert resistance to current therapies that targeting androgen receptor signalling in advanced prostate cancer. With my PhD training I hope to learn more about translating pre-clinical findings to the clinic, and help improve the outcome for men with advanced prostate cancer.

Dr Adam Sharp's group have written 73 publications

Most recent new publication 10/2024

See all their publications

The aim of the Translational Therapeutics Group is to better understand the biology of prostate, and other advanced cancers, to identify therapeutic strategies that can be rapidly translated to ‘proof of concept’ clinical studies to improve treatments for advanced cancer.

Prostate cancer is a common cancer, and despite the development of new treatments that have improved the outcome for patients with advanced disease, it continues to be a common cause of cancer death.

Prostate cancer represents a heterogenous disease with multiple molecular subtypes; a better understanding of the underpinning biology will help support the development of new treatments and novel therapeutic strategies to improve the outcome for patients.

Our current research is primarily focused on advanced lethal prostate cancer. The group works to understand the underpinning biology of common molecular subtypes of prostate cancer and interrogate the clinical importance of these, with the aim of developing novel biomarker-treatment combinations to translate to ‘proof of concept’ clinical studies.

Our current research portfolio is focused on understanding protein homeostasis, RNA splicing, apoptosis, and nuclear hormone receptor signalling in advanced cancers. The group works closely with the Cancer Biomarkers Team, Prostate Targeted Cancer Therapies Group, and Drug Development Unit; and collaborates with other groups across The Institute of Cancer Research, nationally and internationally.

Overall, the Translational Therapeutics Group is focused on better understanding pre-clinical prostate cancer biology to support the development of novel therapeutic strategies that can be rapidly translated to clinical studies to improve treatments for advanced cancer.

Recent discoveries from this group